Publication:
Impaired Kynurenine Pathway in Inflammatory Bowel Disease

dc.contributor.authorPaydaş Hataysal E.
dc.contributor.authorKörez M. K.
dc.contributor.authorGuler E. M.
dc.contributor.authorVatansev H.
dc.contributor.authorBozalı K.
dc.contributor.authorBAŞARANOĞLU M.
dc.contributor.authorVatansev H.
dc.date.accessioned2024-11-20T21:50:12Z
dc.date.available2024-11-20T21:50:12Z
dc.date.issued2024-10-01
dc.description.abstractBackground/Objectives: Inflammatory bowel diseases primarily encompass Crohn’s disease and ulcerative colitis. Insufficient levels of tryptophan cause an imbalance in the gut microbiota, leading to inflammation in the gastrointestinal tract. The main catabolic pathway of tryptophan is the kynurenine pathway. Our study aims to evaluate serum tryptophan, the kynurenine pathway, and oxidative stress parameters, including total oxidant status and total antioxidant capacity, in patients with Crohn’s disease and ulcerative colitis. Methods: The study included 80 follow-up patients in remission diagnosed with Crohn’s disease and ulcerative colitis who attended the Gastroenterology Outpatient Clinic, as well as 78 healthy controls. Serum tryptophan, kynurenine, 3-hydroxykynurenine, 3-hydroxyanthranilic acid, and kynurenic acid levels were measured with liquid chromatography and tandem mass spectrometry (LC-MS/MS). All statistical analysis was performed using R version 4.2.1. Statistical Language. Results: Serum tryptophan, 3-hydroxyanthranilic acid, and total antioxidant capacity were lower in patients with ulcerative colitis and Crohn’s disease compared to those in the control group. The serum total oxidant status in the control group was significantly lower than in patients with Crohn’s disease and ulcerative colitis. Conclusions: The results of our research indicate that tryptophan and kynurenine pathway metabolites could potentially contribute to the pathogenesis of inflammatory bowel diseases.
dc.identifier.citationPaydaş Hataysal E., Körez M. K., Guler E. M., Vatansev H., Bozalı K., BAŞARANOĞLU M., Vatansev H., "Impaired Kynurenine Pathway in Inflammatory Bowel Disease", Journal of Clinical Medicine, cilt.13, sa.20, 2024
dc.identifier.doi10.3390/jcm13206147
dc.identifier.issn2077-0383
dc.identifier.issue20
dc.identifier.pubmed39458097
dc.identifier.scopus85207597285
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85207597285&origin=inward
dc.identifier.urihttps://hdl.handle.net/20.500.12645/39826
dc.identifier.volume13
dc.identifier.wosWOS:001341523000001
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectMedicine
dc.subjectHealth Sciences
dc.subjectFundamental Medical Sciences
dc.subjectKlinik Tıp (Med)
dc.subjectKlinik Tıp
dc.subjectTıp Genel & Dahili
dc.subjectClinical Medicine (Med)
dc.subjectClinical Medicine
dc.subjectMedicine General & Internal
dc.subjectGenel Tıp
dc.subjectGeneral Medicine
dc.subjectCrohn’s disease
dc.subjectinflammatory bowel diseases
dc.subjectkynurenine pathway
dc.subjecttryptophan
dc.subjectulcerative colitis
dc.titleImpaired Kynurenine Pathway in Inflammatory Bowel Disease
dc.typearticle
dspace.entity.typePublication
local.avesis.id55121663-7c14-48fc-bde8-f10e0a7831e6
local.indexed.atPubMed
local.indexed.atWOS
local.indexed.atScopus

Files